John Rim, CEO of Samsung Biologics, revealed that he has an curiosity in buying peptide manufacturing services, that are experiencing surging demand amid the worldwide weight problems remedy craze.
Following the acquisition of the Rockville plant in the USA final yr to answer varied contract manufacturing group (CMO) calls for for prescribed drugs, Rim determined to finalize the groundbreaking of Plant 6 inside this yr.
Rim met with reporters on the JP Morgan Healthcare Convention (JPMHC) 2026 held in San Francisco, USA, on Jan. 13 (native time), and stated, “We’ll proceed to pursue mergers and acquisitions (M&A) as we acquired the Rockville plant in the USA final yr,” including, “As there’s vital demand for glucagon-like peptide (GLP)-1, represented by weight problems medication worldwide, we’ve curiosity in buying peptide factories.” Nonetheless, he added, “The truth that there should not many peptide manufacturing unit properties on the market is a priority,” and “We want M&As that may goal modality and geographical enlargement.”
Samsung Biologics is constant home and abroad investments based on the rise in pharmaceutical CDMO demand. In accordance with market analysis agency EvaluatePharma, the biopharmaceutical market measurement is projected to develop at an annual common of 10% from $565 billion final yr to $921 billion in 2030. Specifically, steady demand development is happening within the 4 main modalities: monoclonal antibodies, multispecific antibodies, antibody-drug conjugates (ADC), and fusion proteins. Accordingly, Samsung Biologics started full operation of Plant 5, the primary manufacturing unit within the second bio campus in Songdo, Incheon, final yr and is reviewing the development of Plant 6. Rim stated, “As we’ve accomplished the acquisition of the U.S. plant, we’re getting ready for the development of Plant 6 as the following step,” including, “Solely board approval stays, and the choice shall be accomplished inside this yr.”
Following the acquisition of the Rockville plant in the USA, he additionally disclosed a twin manufacturing technique. Samsung Biologics determined to amass the Rockville plant in Maryland, USA from GlaxoSmithKline (GSK) for $280 million (roughly 413.6 billion received) in December final yr, and can full the acquisition course of inside the first quarter of this yr. The power is an energetic pharmaceutical ingredient manufacturing unit with a manufacturing capability of 60,000 liters that may produce antibody medication of varied scales. Rim defined, “We secured operational stability by using all 500 native personnel who’ve manufacturing unit operation expertise and experience, and secured idle house for added enlargement to answer future demand will increase,” including, “When it comes to value, manufacturing in Korea is rather more environment friendly, so mass manufacturing shall be achieved in Korea whereas the USA will complement some quantity.”
Samsung Biologics accelerated the enlargement of its contract improvement group (CDO) enterprise whereas launching organoid companies to enter the contract analysis group (CRO) enterprise. Rim emphasised, “In Could final yr, we introduced a plan for spin-off to determine a pure holding firm ‘Samsung Epis Holdings’ by separating a part of the funding division that was liable for managing Samsung Bioepis, a subsidiary engaged within the biosimilar enterprise,” including, “By this division, Samsung Biologics, which has been reborn as a pure CDMO firm, has resolved structural complexity and potential conflicts of curiosity considerations, and after the division, has established a basis for strengthening order competitiveness and enhancing company worth and shareholder worth by specializing in CDMO, its core enterprise.”
